Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact
Calgary, Alberta--(Newsfile Corp. - January 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is proud to announce its participation in two highly anticipated Puerto Rico Investor Summits: Sequire Investor Summit: January 22-23 at the Condado Vanderbilt Hotel. CytoImmune-hosted Event: January 24 at CytoImmune's state-of-the-art facility in San Juan, Puerto Rico. Thomas Smeenk, President & CEO of Hemostemix, will deliver an engaging presentation...
2025-01-20 8:54 AM EST
Hemostemix Settlement via Depository Trust Company Plus OTCQB Update
Calgary, Alberta--(Newsfile Corp. - January 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that the settlement of Hemostemix common share purchases via the Depository Trust Company ("DTC") is now enabled. The Company filed a disclosure document with OTC Markets on Wednesday, January 7, 2025. Hemostemix expects to receive OTCIQ access this week. Upon receipt, the Company will upload its financial statements and MD&A, with...
2025-01-13 9:09 AM EST
Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up
Calgary, Alberta--(Newsfile Corp. - January 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) is pleased to announce amendments to its Manufacturing Services Agreement with CytoImmune Therapeutics ("CytoImmune"). These amendments add Regulatory Consulting and Engineering Services and align payments made by Hemostemix PR Inc. with the policies of both the TSX Venture Exchange and Puerto Rico's ACT 60 Program. Driving Regulatory and Engineering Innovation CytoImmune's regulatory...
2025-01-09 8:36 AM EST
Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% Reimbursement of R&D Expenses in Cash
Calgary, Alberta--(Newsfile Corp. - January 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has incorporated Hemostemix PR Inc., in Puerto Rico, as a wholly owned subsidiary and a domestic for profit corporation. Under Puerto Rico's ACT 60 program, Hemostemix PR Inc. is eligible to file applications for cash reimbursement of up to 50% of its research and development expenses, including clinical trials, economic impact...
2025-01-06 9:10 AM EST
Hemostemix is Up-Listing in the USA to Generate Liquidity
Calgary, Alberta--(Newsfile Corp. - January 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has applied to up-list its shares on the OTCQB Venture Market. Currently listed on the TSXV Exchange, Frankfurt, and the OTC, Hemostemix aims to increase its liquidity by broadening its reach to all investors who trade in the capital markets of the USA, Europe, and Canada. The Company's social media campaign across Instagram,...
2025-01-02 9:10 AM EST
Hemostemix's Social Media Awareness of "Your Fountain of Youth"(TM) Regenerative Medicine Treatments Is Gaining Traction
Calgary, Alberta--(Newsfile Corp. - December 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that its social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X is gaining traction. This campaign aims to share patient success stories, connect with individuals seeking safe and innovative treatments for no-option cardiovascular diseases, and educate the public about Hemostemix as an investment opportunity....
2024-12-31 2:50 PM EST
Hemostemix Drives Social Media Awareness of Its Regenerative Medicine Treatments
Calgary, Alberta--(Newsfile Corp. - December 17, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the launch of its social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X. This campaign aims to share patient success stories, connect with individuals seeking safe and innovative treatments for no-option cardiovascular diseases, and educate the public about Hemostemix as an investment opportunity. Follow...
2024-12-17 11:12 AM EST
Hemostemix Announces $2,725,982 Update to Second Closing
Calgary, Alberta--(Newsfile Corp. - December 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is amending its closing documents to include an additional subscription of $50,000. The combined Offerings resulted in gross proceeds of $2,725,981.77 upon the issuance of 54,519,635 Units. The Offering is subject to all necessary regulatory approvals including acceptance from the Exchange. All securities issued in...
2024-12-03 4:41 PM EST
Hemostemix Announces $2,675,981 Private Placement Including Second Tranche of $833,258
Calgary, Alberta--(Newsfile Corp. - November 28, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its second and final tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $833,258 (the "Offering"). The Offering consisted of the issuance of an aggregate of 16,665,160 Units at a price of $0.05 per Unit. Each Unit consists of one common share in the...
2024-11-28 5:42 PM EST
Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway
Calgary, Alberta--(Newsfile Corp. - November 25, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, focusing on revenue, it has retained social media experts to educate and sell caregivers and individuals suffering from Chronic Limb Threatening Ischemia ("CLTI"), Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy, and Congestive Heart Failure, an ACP-01 treatment, available under special access programs. ACP-01...
2024-11-25 1:43 PM EST
Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement
Calgary, Alberta--(Newsfile Corp. - October 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its first tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $1,842,723 (the "Offering"). The Offering consisted of the issuance of an aggregate of 36,854,475 Units at a price of $0.05 per Unit. Each Unit consists of one common share in the capital of the...
2024-10-31 4:04 PM EDT
Hemostemix's Private Placement
Calgary, Alberta--(Newsfile Corp. - October 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $4,000,000 of financing in tranches from the sale of Common Shares and Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each Warrant entitling the holder to acquire one Common Share at a price of $0.12 per...
2024-10-11 8:29 AM EDT
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01
Calgary, Alberta--(Newsfile Corp. - August 1, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it and CytoImmune Therapuetics ("CytoImmune") today signed a binding and funded definitive Manufacturing Services Agreement that re-establishes production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico.
2024-08-01 10:03 PM EDT
Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four heart and three chronic limb threatening ischemia (CLTI) trials, including one retrospective study of 54 patients, ACP-01 is demonstrated to be safe and statistically efficacious as a treatment of...
2024-06-11 11:06 AM EDT
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility. The Company is also pleased to announce that it has received commitments for $1,800,000 of Units in a non-brokered private placement as more fully described below.
2024-06-03 9:05 AM EDT
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice related to the Company's capital markets strategy. Services include advice on the structure of equity or debt capital financing and the identification of potential future investors. The Company intends...
2024-03-07 4:01 PM EST
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results today. The publication highlights the results of no option critical limb ischemia patients who started the clinical trial with an ulcer, comparing wound healing, amputation, and mortality between the...
2024-02-06 10:08 AM EST
Hemostemix Clarifies its October 3, 2023 News Release
Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to like to clarify its press release of October 3, 2023. It refered to the private placement of $320,125. The Company closed the financing in the amount of $320,385 with the issuance of 2,669,875 units. In connection with that Offering, the Corporation paid eligible finders aggregate fees of $5,750.40 in cash and issued 47,920 finder...
2023-12-29 4:02 PM EST
Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
Calgary, Alberta--(Newsfile Corp. - October 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that Stem Cell Research & Therapy published the Company's seventh peer reviewed study of ACP-01 - the third peer reviewed study of ACP-01 as a treatment for heart disease (ischemic and non-ischemic dilated cardiomyopathy), which demonstrates ACP-01 regenerates and improves cardiac function by up to 24.1% at 12 months in ischemic cardiomyopathy, and regenerates...
2023-10-30 2:16 PM EDT
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000
Calgary, Alberta--(Newsfile Corp. - October 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has amended its $2.5 million 5 year convertible debenture, which originally closed on June 11, 2021 ("CD1") resulting in an expected interest saving of $569,868. The 4 material amendments are summarized as follows: 1) Interest will be amended from 6% per annum to nil (zero) from January 1, 2023 to maturity (June 11, 2026) saving the Company up to $569,868 of...
2023-10-23 10:03 AM EDT